Newly approved hepatitis C virus (HCV) NS3/4A protease inhibitors
These drugs cannot be used alone
These drugs are combined with interferon and ribvirin
Indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype chronic hepatitis C (CHC) in adult patients with compensated
liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.